Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1 1

Status

Recruiting 5Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 1328Neoplasms 998Carcinoma, Non-Small-Cell Lung 865Prostatic Neoplasms 730Colorectal Neoplasms 671Lung Neoplasms 553Leukemia, Myeloid, Acute 475Neoplasm Metastasis 427Pancreatic Neoplasms 426Carcinoma, Hepatocellular 407Ovarian Neoplasms 393Multiple Myeloma 393Stomach Neoplasms 383Recurrence 369Squamous Cell Carcinoma of Head and Neck 327Melanoma 295Uterine Cervical Neoplasms 288Brain Neoplasms 288Triple Negative Breast Neoplasms 273Glioblastoma 263Head and Neck Neoplasms 260Precursor Cell Lymphoblastic Leukemia-Lymphoma 256Endometrial Neoplasms 238Lymphoma 230Esophageal Neoplasms 226Rectal Neoplasms 224Sarcoma 213Carcinoma, Renal Cell 205Colonic Neoplasms 196Lymphoma, Large B-Cell, Diffuse 194

Interventions

nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Sorafenib 1Radiotherapy 1Radiosurgery 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × HCC × Clear all
NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting
40 enrolled

HCC

NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting
300 enrolled

HCC

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting
44 enrolled

HCC

NCT06463444 2024-06-17

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Tongji Hospital

Phase 1 Recruiting
30 enrolled

HCC

NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
30 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡